Childhood-onset Idiopathic Nephrotic Syndrome – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030


 Nephrotic syndrome (NS) is one of the most common chronic kidney diseases in children and is characterized by significant proteinuria, hypoalbuminemia, and edema. The primary, idiopathic form of NS, which accounts for a large portion of NS, often occurs due to a stale infection in infancy/early childhood. The current recommended treatment is cortisone therapy over multiple weeks. Youth NS can be congenital, presenting within the first three months of life. In these children, there is usually a genetic mutation affecting either the podocyte of the glomerular basement membrane, although rarely it can be associated with congenital infections such as cytomegalovirus. Apart from the hereditary form of nephrotic syndrome, many underlying aetiologies can cause nephrotic syndrome, including glomerular disorders, vasculitides, infections, toxins, malignancy, genetic mutations, and most commonly, unknown.

 

The incidence of NS varies in different population groups and is currently reported to be 2 to 7 children in the USA. In several European studies, South Asian children were reported to have a higher incidence of NS than the European population.

 

The competitive landscape of Childhood-onset Idiopathic Nephrotic Syndrome includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Childhood-onset Idiopathic Nephrotic Syndrome across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Childhood-onset Idiopathic Nephrotic Syndrome Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Childhood-onset Idiopathic Nephrotic Syndrome – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Obinutuzumab  Genentech        Phase 2

2          Abatacept         Bristol-Myers Squibb      Phase 2

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033